Current Report Filing (8-k)
January 08 2018 - 8:43AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 8, 2018
Infinity Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)
|
|
|
|
|
Delaware
|
|
000-31141
|
|
33-0655706
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
784 Memorial Drive, Cambridge, MA
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(617) 453-1000
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Forward Looking Statements
This Form
8-K
and the exhibit attached hereto contain forward-looking statements of Infinity Pharmaceuticals, Inc.
(Infinity or the Company) that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Form
8-K
and the exhibit
attached hereto, are forward-looking statements. The words anticipate, believe, estimate, expect, intend, may, plan, predict, project,
target, potential, will, would, could, should, continue, contemplate, or the negative of these terms or other similar expressions are intended to
identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about: the Companys estimate regarding its cash balances for
the year ended December 31, 2017 and other expectations regarding its business, plans, prospects and strategies. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking
statements that the Company makes due to a number of important factors, including those Risk Factors discussed in Infinitys quarterly report on Form
10-Q
filed with the Securities and Exchange Commission
(SEC) on November 7, 2017, and its other filings with the SEC. The forward-looking statements in this Form
8-K
and the exhibit attached hereto represent the Companys views as of the date
of this Form
8-K.
The Company anticipates that subsequent events and development will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the
future, it has no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the Companys views as of any date subsequent to the date of
this Form
8-K.
Item 2.02
|
Results of Operations and Financial Condition.
|
Although it has not finalized its full
financial results for the fourth quarter and fiscal year ended December 31, 2017, the Company announced on January 8, 2018, that it expects to report that it had approximately $57.6 million in cash and investments (unaudited) as of
December 31, 2017.
The information contained in Item 2.02 of this
Form 8-K
is
unaudited and preliminary, and does not present all information necessary for an understanding of the Companys financial condition as of December 31, 2017 and its results of operations for the three months and year ended December 31,
2017. The audit of the Companys consolidated financial statements for the year ended December 31, 2017 is ongoing and could result in changes to the information set forth above.
The information in this Item 2.02 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as
expressly set forth by specific reference in such a filing.
On January 8, 2018, the Company issued a press release announcing
its 2018 business goals and financial guidance. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form
8-K
and is incorporated herein by reference. The information
contained on the websites referenced in the press release is not incorporated herein.
Item 9.01
|
Financial Statements and Exhibits.
|
|
(d)
|
The following exhibit is included in this report:
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
INFINITY PHARMACEUTICALS, INC.
|
|
|
|
|
Date: January 8, 2018
|
|
|
|
By:
|
|
/s/ Seth A. Tasker
|
|
|
|
|
|
|
Seth A. Tasker
|
|
|
|
|
|
|
Vice President, General Counsel
|
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Sep 2023 to Sep 2024